Peptide questions · MariTide
MariTide side effects: what studies and users report
Reviewed Evidence: ModeratePublished by PepVault
The side effects most commonly reported for MariTide are nausea, vomiting and constipation, among 6 the library lists; the library’s evidence on it includes controlled trials in people.
Its safety note opens: MariTide has no label: it is still in trials.
What is commonly reported with MariTide
- Nausea
- Vomiting
- Constipation
- Diarrhea
- Indigestion
- Bloating
Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.
| Effect | Also listed for (of 28) |
|---|---|
| Nausea | 24: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 20 more |
| Vomiting | 20: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 16 more |
| Constipation | 14: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 10 more |
| Diarrhea | 23: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 19 more |
| Indigestion | 3: Dulaglutide, Exenatide, Orforglipron |
| Bloating | None: listed for MariTide alone |

Model. Individual results vary.
Which MariTide side effects the metabolic & GLP-1 group shares
Across the 29 metabolic & GLP-1 compounds in the library, the effects listed most often are nausea (25 of 29), diarrhea (24 of 29), vomiting (21 of 29) and constipation (15 of 29). MariTide shares 5 of its 6 listed effects with at least one other metabolic & GLP-1 compound; bloating is listed for MariTide alone.
What the MariTide safety notes say
The library’s safety note
MariTide has no label: it is still in trials. In its 52-week phase 2 trial, the most common side effects were GI (nausea, vomiting, constipation), mostly mild to moderate and mostly around the first doses. They were less frequent when the dose was stepped up and started lower, and in the step-up groups nausea, when it came, usually settled within about 6 days and vomiting within 1 to 2 days. About 11% in the step-up groups stopped for any side effect, and up to 7.8% for GI ones. Amgen reported no link to changes in bone density and no new safety signals, and tolerability in line with the GLP-1 class. It is a GLP-1 drug, so the class warnings in GLP-1 labels (including pancreatitis, gallbladder disease and the rodent thyroid C-cell finding) are the ones to read. These are trial findings to review with your clinician.
The library’s interaction note
No interaction results have been published; Amgen has run studies of its effect on stomach emptying and on oral contraceptives (NCT07429032, NCT07523711). GLP-1 drugs slow stomach emptying, which can change how oral medicines are absorbed. It is a GLP-1 drug itself, so it is not stacked with another one. With insulin or a sulfonylurea, discuss glucose monitoring with your clinician.
These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.
Where the MariTide reports come from
The library rates the evidence on MariTide as moderate: animal studies plus some human data.
Of the library’s 8 research notes on MariTide, 3 rest on randomized trials, 4 on clinical data and 1 on community reports.
So MariTide has controlled trials in people to set its listed effects against.
Questions people ask
What are the side effects of MariTide?
The side effects most commonly reported for MariTide are nausea, vomiting and constipation, among 6 the library lists; the library’s evidence on it includes controlled trials in people.
Do MariTide’s side effects come from human studies?
The library rates the evidence on MariTide as moderate, and the library’s evidence on it includes controlled trials in people.
Which MariTide side effects are its own?
Among the metabolic & GLP-1 compounds, the library lists bloating for MariTide alone.
Does MariTide interact with other medicines?
The library’s interaction note on MariTide begins: No interaction results have been published; Amgen has run studies of its effect on stomach emptying and on oral contraceptives (NCT07429032, NCT07523711).